This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Disease-modifying treatment

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Seek expert advice

Treatments which modify the progression of systemic sclerosis may be classified into three groups:

  • specific immunosuppressant therapy:
    • cyclosporin A:
      • good for skin but bad for kidneys
    • antithymocyte globulin:
      • good for skin
    • plasmapheresis:
      • anecdotal evidence only
  • global immunosuppressant therapy:
    • methotrexate
    • corticosteroids
    • alkylating agents e.g. azathioprine, cyclophosphamide
    • ritixumab
      • study suggest that rituximab treatment may provide long-term benefit for patients with systemic sclerosis, and serum immunoglobulins should be explored as potential response markers (1)

  • anti-fibrotic therapy:
    • D-penicillamine:
      • good for lung, skin and kidney
    • interferons alpha & gamma:
    • probably beneficial, but morbidity with interferons is significant

Reference:

  • Kuzumi A, Ebata S, Fukasawa T, et al. Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis: Follow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels. JAMA Dermatol. Published online February 15, 2023. doi:10.1001/jamadermatol.2022.6340

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.